
Life Sciences are the profession of the future
Interview with Prof. Shulamit Michaeli, Israel Prize Laureate for 2026 in the Life Sciences and alumna of the Faculty of Life Sciences at Tel Aviv University, about discoveries, choices and the profession of the future.
Editor and interviewer: Eilat Elgur Gurfinkel, alumna of Journalism Studies at TAU
Translator: Michal Alexander
Photo: Muki Schwartz
“Life Sciences will change life on this planet.”
From the judges’ citation
Prof. Michaeli is a global pioneer in research on parasite RNA and a trailblazer in the study of RNA, its various forms and their functions, with a focus on pathogenic parasites impacting human populations in many regions of the world. Her groundbreaking studies have opened new avenues for understanding the function of modifications in small non-coding RNA molecules. She continues to work at an impressive pace, and her papers, published in world-leading journals, drive important improvements in medical treatments for diseases caused by these parasites.
Prof. Michaeli has contributed significantly to the advancement of scientific research in Israel. She has played a role in a range of influential national operations and established a future generation of academic researchers who work both in Israel and worldwide.
The Prize Committee, headed by Prof. Elisha Haas, highlighted her status as a global pioneer combining basic research with medical applications.
Prof. Michaeli: “The motivation for conducting research is immense. I dreamed of understanding phenomena. I wanted to make discoveries. People were very emotional about the Israel Prize ceremony. These are difficult times, and suddenly something good happens, filling people with hope.”
Profile
Born: 1955 in Givatayim. Lives in Kiryat Ono, Israel.
Academic education
- 1979–1984: Student in TAU’s first Direct Track to a PhD in Microbiology.
- Postdoctoral researcher at UC Berkeley and San Francisco Medical School.
National forums
- Since 2025: Member of VATAT, the Planning and Budgeting Committee of the Israel Council for Higher Education.
- 2019–2025: Head of the Medical Division at the Israel Science Foundation.
Career
- 2017–2024: Vice President of Research, Bar-Ilan University.
- 2013–2018: Dean of the Faculty of Life Sciences, Bar-Ilan University.
- 1990–1998: Faculty member at the Weizmann Institute of Science, where she received a professorship.
- 1990: Given her own laboratory at the Weizmann Institute.
- 1985: Left TAU’s Department of Microbiology.
Selected international studies and grants
- 2022: Prestigious ERC Synergy grant from the European Research Council with researchers from the Weizmann Institute and Pasteur Institute.
- 2010–2015: Participant in the European project Save Me.
- 2000–2010: Howard Hughes Medical Institute International Research Scholars Program and a research grant from the Israel National Nanotechnology Initiative.
Collaborations with TAU
- 2010–2011: Israel Innovation Authority project led by Tel Aviv University, building a new technological infrastructure in nanomedicine for commercialization and industrial applications. Prof. Michaeli headed a team that partnered with Prof. Dan Peer of TAU.
- 2010: Began developing a nanomedical treatment for leishmaniasis as part of an INNI project.
- 2010–2011: Rimonim, a consortium established by Israel’s Chief Scientist to develop technologies for delivering gene-silencing RNA molecules to cancer cells.
Collaborations with the Weizmann Institute
- 2023: Trailblazing studies on ribosomes with Nobel laureate Prof. Ada Yonath.
- 2023: Collaboration with Prof. Yitzhak Pilpel as part of ERC Synergy.
Awards and recognition
- 2026: Israel Prize in the Life Sciences.
- 2025: Elected one of Givatayim’s 100 outstanding daughters on the city’s centennial.
- 2023: Ephraim Katzir Prize.
- 2022: One of the 50 most influential women chosen by Globes.
- 2012: Globes Woman of the Year.
- 2010: Landau Prize.
- 2000: French Academy of Sciences Prize for contribution to understanding basic processes in Trypanosoma parasites.
“I belong to a large group of scientists around the world and a smaller group in Israel who recognized that RNA plays a major role in regulating protein synthesis in cells.”
Did your family background impact your professional choices?
I come from a family of rabbis and dayanim, and apparently learning is in my genes. In high school I majored in biology and later deliberated between medicine, chemistry and biology. I chose biology and I’m very happy I did.
What vital choices did you make at the start of your career?
During my undergraduate studies, there was a time when I thought I would focus on plants. However, a seminar on bacteria entitled “Analysis of Experimental Results,” taught by Professor Eliora Ron, transformed my thinking and my dreams. It changed my life. I decided to become a microbiologist.
After completing my PhD, I wanted to continue in microbiology, studying systems of higher cells that resemble human cells. I chose molecular parasitology, focusing on the Great Neglected Diseases, a range of diseases not yet eradicated. To this day I work on pathogenic parasites that affect millions around the world.
Which of your research projects do you consider most important?
I study RNA. Cells of living organisms contain the genetic material DNA, proteins, and messenger RNA, which carries information for protein production from the DNA. For many years, RNA was viewed merely as a messenger, while non-coding RNA molecules, which do not carry instructions for protein synthesis, were largely overlooked. I belong to a large group of scientists around the world and a smaller group in Israel who recognized that RNA also plays a major role in regulating protein synthesis in cells.
In the early 2000s, I started investigating RNA molecules that guide chemical modifications on other RNA molecules. For one of these modifications, called pseudouridine, at the time identified primarily on long-lived RNA molecules, I demonstrated presence on short-lived RNA molecules as well. Years later this modification was incorporated into the mRNA used in COVID-19 vaccines and was a key factor in their success.
In 2022 I joined Professor Ada Yonath of the Weizmann Institute of Science, awarded the Nobel Prize for deciphering the structure and function of the ribosome, the cellular machine that translates genetic information into protein synthesis. Together we investigated the effects of RNA-guided chemical modifications on the ribosome and its RNA. We showed that even a single modification in the ribosome can alter patterns of protein synthesis, enabling pathogenic parasites to adapt to changes in their environment. This has been one of the most important projects of my career.
Another key focus of my efforts has been the Leishmania parasite that causes the skin disease cutaneous leishmaniasis, commonly known in Israel as the “Jericho Rose” disease. While the disease still affects millions in a hundred countries worldwide, including Israel, no effective, non-toxic, easily accessible treatment is yet available. Many IDF soldiers stung by sand flies suffered considerably from painful leishmaniasis lesions during the Iron Swords war.
In 2010, together with researchers from TAU and supported by a grant from the Israel National Nanotechnology Initiative, I began developing a nanotechnology-based treatment for this disease, as well as for sleeping sickness. I developed an effective therapeutic ointment called NANO-LISH-IL, which was successfully tested in animals in 2021 and is now undergoing clinical trials. My dream is to bring this treatment to the stage of mass production and make it widely available.
I was also a member of the Rimonim consortium established in 2010 by Israel’s Chief Scientist to develop technologies for delivering gene-silencing RNA molecules to cancer cells. Working with TAU researchers Prof. Dan Peer and Prof. Ronit Satchi-Fainaro, we developed a nanocarrier with a polymer that bonds RNA and used it in injections, primarily for ovarian cancer. Later I applied this technology to infectious diseases, and I still work on RNA delivery for treating various skin diseases. I believe that RNA control will be an integral part of natural medical therapies. As we saw with the successful COVID vaccine, this is the future.
“I believe that RNA control will play a part in natural medical therapies. This is the future.”
What is your message to TAU alumni?
I believe that Life Sciences will change life on our planet, through medical innovations and drug development, as well as food security and plant resilience.
In my day, most employment opportunities for graduates of life sciences were found in academia. Today Israel has a thriving biotechnology industry. Graduates are sought by numerous biotechnology and bioconvergence startups and companies, developing anything from synthetic milk and honey to human organs. At the same time, academic researchers lead global breakthroughs, such as developing organs and tissue for transplantation. Hospitals are also very active in research. There is great demand for biologists who are also trained in AI and computer science.
I believe that this is the profession of the future. All medications from antibiotics to immunotherapy emerge from basic research in our labs. Without basic science and innovations in bioconvergence doctors will not have new drugs for clinical treatments. Biologists and bioinformatics experts play a major role in personalized medicine, and modern diagnostics also involve advanced technologies. For example, deep sequencing analysis, requiring sequencing technologies, lab work, and bioinformatics, allows for prenatal diagnosis of genetic mutations.
I am extremely optimistic about the future of my profession.
Originally published by the Tel Aviv University Alumni Organization.

